Cyclo Therapeutics, Inc. (CYTH)
USD 0.72
(0.0%)
USD 0.72
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -2.41 Million USD | -294.87% |
| 2022 | 1.23 Million USD | -13.49% |
| 2021 | 1.42 Million USD | 70.81% |
| 2020 | 836.97 Thousand USD | -10.17% |
| 2019 | 931.7 Thousand USD | 2.79% |
| 2018 | 906.45 Thousand USD | -17.96% |
| 2017 | 1.1 Million USD | -15.3% |
| 2016 | 1.3 Million USD | 57.92% |
| 2015 | 826.03 Thousand USD | -36.2% |
| 2014 | 1.29 Million USD | 2.17% |
| 2013 | 1.26 Million USD | 39.99% |
| 2012 | 905.26 Thousand USD | 19.41% |
| 2011 | 758.09 Thousand USD | 10.23% |
| 2010 | 687.71 Thousand USD | 34.05% |
| 2009 | 513.04 Thousand USD | 29.68% |
| 2008 | 395.61 Thousand USD | -37.48% |
| 2007 | 632.77 Thousand USD | 51.7% |
| 2006 | 417.12 Thousand USD | 7.59% |
| 2005 | 387.7 Thousand USD | 0.48% |
| 2004 | 385.86 Thousand USD | 10.53% |
| 2003 | 349.09 Thousand USD | -20.28% |
| 2002 | 437.88 Thousand USD | 71.45% |
| 2001 | 255.39 Thousand USD | -10.5% |
| 2000 | 285.36 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -808.02 Thousand USD | -27.44% |
| 2024 Q1 | -634.03 Thousand USD | -12.19% |
| 2023 FY | -2.41 Million USD | -294.87% |
| 2023 Q1 | 142.21 Thousand USD | -16.85% |
| 2023 Q2 | 97.2 Thousand USD | -31.65% |
| 2023 Q4 | -565.15 Thousand USD | -223.74% |
| 2023 Q3 | 456.71 Thousand USD | 369.82% |
| 2022 Q1 | 178.44 Thousand USD | -65.45% |
| 2022 FY | 1.23 Million USD | -13.49% |
| 2022 Q4 | 171.03 Thousand USD | -59.19% |
| 2022 Q3 | 419.13 Thousand USD | -10.48% |
| 2022 Q2 | 468.21 Thousand USD | 162.4% |
| 2021 Q3 | 381.24 Thousand USD | 82.91% |
| 2021 Q2 | 208.43 Thousand USD | -35.58% |
| 2021 FY | 1.42 Million USD | 70.81% |
| 2021 Q1 | 323.53 Thousand USD | 148.6% |
| 2021 Q4 | 516.46 Thousand USD | 35.47% |
| 2020 Q2 | 196.64 Thousand USD | -34.3% |
| 2020 FY | 836.97 Thousand USD | -10.17% |
| 2020 Q3 | 210.88 Thousand USD | 7.24% |
| 2020 Q4 | 130.14 Thousand USD | -38.29% |
| 2020 Q1 | 299.3 Thousand USD | 39.4% |
| 2019 Q1 | 200.27 Thousand USD | -11.09% |
| 2019 Q3 | 259.94 Thousand USD | 1.23% |
| 2019 Q4 | 214.7 Thousand USD | -17.4% |
| 2019 FY | 931.7 Thousand USD | 2.79% |
| 2019 Q2 | 256.78 Thousand USD | 28.22% |
| 2018 Q1 | 174.39 Thousand USD | 13.54% |
| 2018 Q3 | 211.43 Thousand USD | -28.42% |
| 2018 Q4 | 225.24 Thousand USD | 6.53% |
| 2018 FY | 906.45 Thousand USD | -17.96% |
| 2018 Q2 | 295.37 Thousand USD | 69.37% |
| 2017 Q2 | 444.06 Thousand USD | 55.44% |
| 2017 Q1 | 285.67 Thousand USD | -36.95% |
| 2017 Q4 | 153.6 Thousand USD | -30.65% |
| 2017 FY | 1.1 Million USD | -15.3% |
| 2017 Q3 | 221.48 Thousand USD | -50.12% |
| 2016 Q4 | 453.1 Thousand USD | 83.22% |
| 2016 Q1 | 275.85 Thousand USD | 93.01% |
| 2016 FY | 1.3 Million USD | 57.92% |
| 2016 Q2 | 328.21 Thousand USD | 18.98% |
| 2016 Q3 | 247.3 Thousand USD | -24.65% |
| 2015 Q2 | 322.93 Thousand USD | 114.24% |
| 2015 Q1 | 150.73 Thousand USD | -52.09% |
| 2015 Q4 | 142.92 Thousand USD | -31.76% |
| 2015 FY | 826.03 Thousand USD | -36.2% |
| 2015 Q3 | 209.44 Thousand USD | -35.14% |
| 2014 FY | 1.29 Million USD | 2.17% |
| 2014 Q1 | 439.91 Thousand USD | 121.47% |
| 2014 Q4 | 314.58 Thousand USD | -7.79% |
| 2014 Q3 | 341.14 Thousand USD | 126.49% |
| 2014 Q2 | 150.62 Thousand USD | -65.76% |
| 2013 Q3 | 138.19 Thousand USD | -75.45% |
| 2013 Q4 | 198.63 Thousand USD | 43.73% |
| 2013 Q2 | 562.81 Thousand USD | 53.08% |
| 2013 Q1 | 367.66 Thousand USD | 12.03% |
| 2013 FY | 1.26 Million USD | 39.99% |
| 2012 Q3 | 130.34 Thousand USD | 9.13% |
| 2012 Q4 | 328.17 Thousand USD | 151.78% |
| 2012 Q2 | 119.43 Thousand USD | -63.51% |
| 2012 Q1 | 327.31 Thousand USD | 115.63% |
| 2012 FY | 905.26 Thousand USD | 19.41% |
| 2011 FY | 758.09 Thousand USD | 10.23% |
| 2011 Q1 | 207.67 Thousand USD | -11.32% |
| 2011 Q2 | 191.8 Thousand USD | -7.64% |
| 2011 Q3 | 206.81 Thousand USD | 7.82% |
| 2011 Q4 | 151.79 Thousand USD | -26.6% |
| 2010 Q3 | 163.36 Thousand USD | 18.08% |
| 2010 Q1 | 144.53 Thousand USD | 15.72% |
| 2010 FY | 687.71 Thousand USD | 34.05% |
| 2010 Q2 | 138.35 Thousand USD | -4.28% |
| 2010 Q4 | 234.17 Thousand USD | 43.35% |
| 2009 Q3 | 176.1 Thousand USD | 63.56% |
| 2009 FY | 513.04 Thousand USD | 29.68% |
| 2009 Q1 | 104.37 Thousand USD | -1.22% |
| 2009 Q2 | 107.66 Thousand USD | 3.16% |
| 2009 Q4 | 124.89 Thousand USD | -29.08% |
| 2008 Q1 | 47.92 Thousand USD | -64.6% |
| 2008 Q4 | 105.65 Thousand USD | -23.99% |
| 2008 Q3 | 138.99 Thousand USD | 42.94% |
| 2008 Q2 | 97.23 Thousand USD | 102.88% |
| 2008 FY | 395.61 Thousand USD | -37.48% |
| 2007 Q3 | 181.11 Thousand USD | 8.33% |
| 2007 FY | 632.77 Thousand USD | 51.7% |
| 2007 Q4 | 135.38 Thousand USD | -25.25% |
| 2007 Q2 | 167.18 Thousand USD | 12.12% |
| 2007 Q1 | 149.12 Thousand USD | 23.66% |
| 2006 Q2 | 89.49 Thousand USD | -29.31% |
| 2006 FY | 417.12 Thousand USD | 7.59% |
| 2006 Q4 | 120.59 Thousand USD | 49.91% |
| 2006 Q3 | 80.44 Thousand USD | -10.11% |
| 2006 Q1 | 126.59 Thousand USD | 112.89% |
| 2005 FY | 387.7 Thousand USD | 0.48% |
| 2005 Q1 | 101.07 Thousand USD | 58.09% |
| 2005 Q2 | 123.66 Thousand USD | 22.35% |
| 2005 Q3 | 103.5 Thousand USD | -16.3% |
| 2005 Q4 | 59.46 Thousand USD | -42.55% |
| 2004 Q4 | 63.93 Thousand USD | -38.6% |
| 2004 FY | 385.86 Thousand USD | 10.53% |
| 2004 Q3 | 104.12 Thousand USD | -3.58% |
| 2004 Q2 | 107.99 Thousand USD | -1.66% |
| 2004 Q1 | 109.81 Thousand USD | -30.28% |
| 2003 Q1 | 42.62 Thousand USD | -6.02% |
| 2003 FY | 349.09 Thousand USD | -20.28% |
| 2003 Q4 | 157.5 Thousand USD | 105.36% |
| 2003 Q3 | 76.7 Thousand USD | 6.13% |
| 2003 Q2 | 72.26 Thousand USD | 69.55% |
| 2002 Q4 | 45.35 Thousand USD | -64.17% |
| 2002 Q2 | 105.19 Thousand USD | -34.56% |
| 2002 Q1 | 160.75 Thousand USD | 264.17% |
| 2002 Q3 | 126.58 Thousand USD | 20.32% |
| 2002 FY | 437.88 Thousand USD | 71.45% |
| 2001 Q2 | 78.61 Thousand USD | 3.34% |
| 2001 Q1 | 76.07 Thousand USD | 51.09% |
| 2001 FY | 255.39 Thousand USD | -10.5% |
| 2001 Q4 | 44.14 Thousand USD | -21.68% |
| 2001 Q3 | 56.36 Thousand USD | -28.31% |
| 2000 Q3 | 63.27 Thousand USD | 0.0% |
| 2000 FY | 285.36 Thousand USD | 0.0% |
| 2000 Q4 | 50.35 Thousand USD | -20.43% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 100.739% |
| Embecta Corp. | 749.9 Million USD | 100.321% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 100.789% |
| Dynavax Technologies Corporation | 182.11 Million USD | 101.323% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 103.299% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 100.492% |
| PainReform Ltd. | -15 Thousand USD | -15967.84% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | 108.101% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | 128.902% |
| SCYNEXIS, Inc. | 124.51 Million USD | 101.936% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | 535.073% |
| Cosmos Health Inc. | 4.34 Million USD | 155.412% |
| Journey Medical Corporation | 52.52 Million USD | 104.589% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | 128.902% |
| Safety Shot Inc | -74.45 Thousand USD | -3137.004% |
| Alpha Teknova, Inc. | 10.29 Million USD | 123.409% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 100.56% |
| Bright Green Corporation | -237.01 Thousand USD | -916.883% |
| Procaps Group, S.A. | 239.56 Million USD | 101.006% |
| Theratechnologies Inc. | 62.12 Million USD | 103.879% |
| Harrow Health, Inc. | 90.55 Million USD | 102.662% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | 150.794% |
| Biofrontera Inc. | 16.62 Million USD | 114.496% |
| DURECT Corporation | 6.83 Million USD | 135.283% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 100.46% |
| Cronos Group Inc. | 6.99 Million USD | 134.476% |
| OptiNose, Inc. | 62.35 Million USD | 103.865% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 100.546% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | -695.438% |
| RedHill Biopharma Ltd. | 3.05 Million USD | 178.914% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 100.778% |
| Guardion Health Sciences, Inc. | 5.39 Million USD | 144.678% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | 107.198% |
| Radius Health, Inc. | 307.71 Million USD | 100.783% |
| Universe Pharmaceuticals INC | 10.07 Million USD | 123.916% |
| ProPhase Labs, Inc. | 16.23 Million USD | 114.842% |
| Phibro Animal Health Corporation | 312.48 Million USD | 100.771% |
| Procaps Group S.A. | 239.56 Million USD | 101.006% |
| Alvotech | -69.42 Million USD | 96.528% |
| TherapeuticsMD, Inc. | 1.3 Million USD | 285.113% |
| Viatris Inc. | 6.43 Billion USD | 100.037% |
| Rockwell Medical, Inc. | 8.7 Million USD | 127.69% |
| Aytu BioPharma, Inc. | 54.58 Million USD | 104.415% |
| SIGA Technologies, Inc. | 122.09 Million USD | 101.974% |
| Tilray Brands, Inc. | 223.35 Million USD | 101.079% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | 105.759% |
| Shineco, Inc. | 882.16 Thousand USD | 373.211% |
| PetIQ, Inc. | 252.74 Million USD | 100.954% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | -223.258% |
| Incannex Healthcare Limited | 12 Thousand USD | 20184.8% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 100.13% |
| Alimera Sciences, Inc. | 61.17 Million USD | 103.94% |
| Silver Spike Investment Corp. | 8.1 Million USD | 129.746% |
| Assertio Holdings, Inc. | 125.04 Million USD | 101.927% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | -35286.522% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | 157.506% |
| Clever Leaves Holdings Inc. | 6.55 Million USD | 136.763% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | 108.888% |
| Hempacco Co., Inc. | -1.21 Million USD | -98.232% |
| Talphera, Inc. | -4.89 Million USD | 50.762% |
| Alvotech | -69.42 Million USD | 96.528% |
| Eagle Pharmaceuticals, Inc. | 221.67 Million USD | 101.087% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 100.34% |
| Currenc Group, Inc. | 17.35 Million USD | 113.886% |
| Kamada Ltd. | 52.59 Million USD | 104.583% |
| Indivior PLC | 907 Million USD | 100.266% |
| Evoke Pharma, Inc. | 4.97 Million USD | 148.409% |
| Flora Growth Corp. | 17.73 Million USD | 113.588% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | -0.0% |
| Evolus, Inc. | 140.52 Million USD | 101.715% |
| HUTCHMED (China) Limited | 453.55 Million USD | 100.531% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 100.701% |
| Akanda Corp. | 111.44 Thousand USD | 2262.582% |